Hepatitis C in the interferon-free era

Streinu-Cercel, Adrian
December 2013
Germs;Dec2013, Vol. 3 Issue 4, p114
Academic Journal
The editor discusses the in-depth study of the genetic structure of hepatitis C virus (HCV) which described the viral life cycle and the ideal targets for direct-acting antivirals (DAAs). Topics discussed include enzymatic targets for antivirals attacks, viral proteins role in establishing infectivity, host cell apoptosis along with intra-cellular signaling and viral replication. It mentions the name of companies which has registered clinical trials in the field of HCV.


Related Articles

  • Antiviral Resistance and the Future Landscape of Hepatitis C Virus Infection Therapy. Wyles, David L. // Journal of Infectious Diseases;Mar2013, Vol. 207 Issue suppl_1, pS33 

    The addition of hepatitis C virus (HCV) protease inhibitors (PIs) to interferon and ribavirin therapy has significantly improved the efficacy of treatment for HCV infection. However, for patients who do not respond to therapy, the selection of HCV variants with resistance to PIs is likely....

  • New treatments for genotype I chronic hepatitis C - focus on simeprevir. Kanda, Tatsuo; Nakamoto, Shingo; Wu, Shuang; Yokosuka, Osamu // Therapeutics & Clinical Risk Management;2014, Vol. 10, p387 

    Chronic hepatitis C virus (HCV) infection causes end-stage liver diseases and hepatocellular carcinoma. In the USA, Canada, and Japan, simeprevir - one of the second -generation HCV NS3/4A protease inhibitors - in combination with peginterferon а-2a or 2b plus ribavirin has recently been...

  • Targeting NS5B RNA-Dependent RNA Polymerase for Anti-HCV Chemotherapy. Jim Z. Wu; Zhi Hong // Current Drug Targets - Infectious Disorders;Sep2003, Vol. 3 Issue 3, p207 

    The global prevalence of persistent hepatitis C virus (HCV) infection and the lack of a highly effective and well-tolerated antiviral therapy have spurred intensive efforts to discover and develop novel anti-HCV therapy in the pharmaceutical industry. HCV NS5B RNA-dependent RNA polymerase...

  • Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in Hepatitis C virus replicon. Hazari, Sidhartha; Taylor, Lizeth; Haque, Salima; Garry, Robert F.; Florman, Sander; Luftig, Ronald; Regenstein, Frederic; Dash, Srikanta // Virology Journal;2007, Vol. 4, p89 

    Background: Alpha interferon in combination with ribavirin is the standard therapy for hepatitis C virus infection. Unfortunately, a significant number of patients fail to eradicate their infection with this regimen. The mechanisms of IFN-resistance are unclear. The aim of this study was to...

  • Prediction of prognostic biomarkers for Interferon-based therapy to Hepatitis C Virus patients: a metaanalysis of the NS5A protein in subtypes 1a, 1b, and 3a. ElHefnawi, Mahmoud M.; Zada, Suher; El-Azab, Iman A. // Virology Journal;2010, Vol. 7, p130 

    Background: Hepatitis C virus (HCV) is a worldwide health problem with no vaccine and the only approved therapy is Interferon-based plus Ribavarin. Response prediction to treatment has health and economic impacts, and is a multi-factorial problem including both host and viral factors (e.g: age,...

  • Recent Advances in Hepatitis C Virus Treatment: Review of HCV Protease Inhibitor Clinical Trials. Chary, Aarthi; Holodniy, Mark // Reviews on Recent Clinical Trials;Sep2010, Vol. 5 Issue 3, p158 

    Hepatitis C virus (HCV) infection affects millions of people world-wide, and chronic infection can result in end-stage liver disease and hepatocellular carcinoma. Conventional therapy to date has involved combination antiviral therapy including alpha-interferon and ribavirin; response rates with...

  • Anti-infectives: New oral HCV drug shows promise. Man Tsuey Tse // Nature Reviews Microbiology;Jul2010, Vol. 8 Issue 7, p464 

    The article reports on a study which demonstrated the potent antiviral effects of BMS-790052, a new first-in-class compound for hepatitis C virus (HCV) infection. The drug was evaluated in a Phase I clinical trial of patients chronically infected with HCV. The results suggest that the agent...

  • How INFORM-1 May Change HCV Drug Development. Morrison, Trista // BioWorld Financial Watch;5/4/2009, Vol. 17 Issue 18, p1 

    The article discusses preliminary data on INFORM-1, the first study to combine two direct-acting antivirals for hepatitis C, which was presented at the 44th annual meeting of the European Association for the Study of the Liver (EASL). The encouraging outcomes of the trial are identified, such as...

  • EASL Roundup.  // BioWorld Today;4/27/2009, Vol. 20 Issue 79, p3 

    The article reports on the positive results from a Phase 1b single-agent study of oral antiviral drug, candidate, SCY-365, a cyclophilin inhibitor from Scynexis Inc. in adult patients with genotype 1 chronic hepatitis C virus (HCV). SCY-635 was said to be well tolerated with no serious adverse...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics